This spring, the guidelines committee of the Dutch Federation for Nephrology (NFN) published the ‘Guidance on SGLT2 inhibitors in patients with chronic kidney damage without diabetes mellitus type 2’. The demonstrated protective effect of SGLT2 inhibitors with regard to cardiovascular disease and deterioration of renal function in patients with chronic kidney damage (CNS) without diabetes and the reimbursement of dapagliflozin for all people with CNS gave rise to this, according to Lily Jakulj, internist-nephrologist in Amsterdam UMC and Dianet Amsterdam and leader of the working group. She explains for which patients with CNS SGLT2 inhibition is useful.
More information is only accessible to subscribers who are authorized to prescribe.
Login
NB: To view all information you need an account to log in. Are you already logged in? Then you do not have sufficient rights to view this information. Do you want to adjust your account? Then click here
2023-10-31 15:16:51
#SGLT2 #inhibition #patients #chronic #kidney #damage #diabetes #MedNet
